Research
Services
Bioculture Group delivers integrated preclinical and translational research services that bridge ethical animal science with advanced biomedical innovation.
Through Franklin Biolabs and AnewCRO, our research network supports gene therapy, pharmacology, and safety assessment studies that accelerate the path from discovery to cure.
Bioculture’s research framework is built on precision, reproducibility, and responsibility.
Our goal is to create a continuum of scientific services, from preclinical design to regulatory submission, that empowers clients to move therapies from concept to clinical application faster and more ethically.
We provide both discovery and IND enabling programs across in vivo & molecular research platforms.
Our multidisciplinary teams combine decades of experience in pharmacology, toxicology, and genetic medicine to deliver validated & reproducible results.
Every study is conducted under robust quality standards supported by secure, validated data systems and external audits to ensure transparency, regulatory compliance and scientific accuracy.
Every client engagement is customized - from study design to data delivery, ensuring confidentiality and proactive communication
Our Research Companies
Franklin Biolabs and AnewCRO complement one another within Bioculture’s Care to Cure ecosystem, integrating the ethical sourcing of NHPs with cutting-edge preclinical research and translational expertise. Together, they provide a full-service continuum:
A next-generation preclinical and genetic medicine CRO specializing in cell and gene therapy, biologics, and RNA-based therapeutics.
Franklin Biolabs provides GLP-compliant toxicology, PK/PD, and bioanalytic studies with advanced AAV vector development and bioassay capabilities.
An NHP-based preclinical CRO focused on pharmacology, toxicology, ocular, and neuroscience research.
AnewCRO provides discovery and non-GLP toxicology programs, supporting early-stage drug candidate screening and formulation refinement.
Quality Assurance
Bioculture Group maintains the highest standards of scientific, ethical, and operational quality across all research entities.
Research programs are conducted under robust scientific and quality standards appropriate to early-stage discovery and non-clinical development. Study designs and data practices are aligned to support downstream GLP studies and regulatory pathways led by sponsors or partner organisations.
SOP-driven study management and documentation.
Regular calibration and validation of laboratory equipment.
Real-time digital auditing for traceability and reproducibility.
Secure, validated data systems ensure transparency, regulatory compliance, and scientific accuracy. Each study undergoes internal review and quality verification prior to client submission.
Franklin Biolabs and AnewCRO adhere to AAALAC International, OLAW, and IACUC welfare standards.
Independent external audits verify compliance annually.
Research Capabilities
Bioculture Group delivers advanced preclinical and translational research capabilities designed to support the earliest and most critical stages of biomedical development. Our research activities are focused on generating high-quality, reproducible data that informs discovery decisions, enables non-clinical development, and supports regulatory progression toward first-in-human studies.
By combining ethically sourced non-human primate models with rigorous study design, advanced analytics, and specialised genetic medicine platforms, we provide an integrated research environment where scientific precision, traceability, and regulatory readiness are embedded at every stage. Our capabilities are purpose-built to meet the evolving needs of pharmaceutical, biotechnology, and academic partners developing complex and innovative therapies.
- Preclinical Safety and Toxicology: GLP and non-GLP studies supporting IND filings.
- Pharmacokinetic (PK) and Pharmacodynamic (PD) Assessments: Determining drug absorption, distribution, metabolism, and efficacy.
- Gene and Cell Therapy Development: AAV, RNA, and viral vector studies for genetic medicine programs.
- Controlled preclinical design using standardized NHP models.
- Advanced analytical instrumentation for bioanalysis and vector quantification.
- Robust digital data capture systems ensuring traceability and reproducibility.
Neurodegenerative disorders (Alzheimer’s, Parkinson’s), Ocular diseases (Retinal degeneration, glaucoma), Gene & Cell therapy, Metabolic syndromes, Viral infections, immune disorders, Oncology, Vaccine development, behavioral and neuroscience research.
